Frontiers in epidemiologyPub Date : 2026-10-30eCollection Date: 2026-01-01DOI: 10.3389/fepid.2026.1963125
Minji Sohn
{"title":"Editorial: Pharmacoepidemiology in chronic diseases.","authors":"Minji Sohn","doi":"10.3389/fepid.2026.1963125","DOIUrl":"https://doi.org/10.3389/fepid.2026.1963125","url":null,"abstract":"","PeriodicalId":73083,"journal":{"name":"Frontiers in epidemiology","volume":"6 ","pages":"1963125"},"PeriodicalIF":2.9,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13759724/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149413688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in epidemiologyPub Date : 2026-10-29eCollection Date: 2026-01-01DOI: 10.3389/fepid.2026.1919766
Jun Liu, Yi Wang, Shasha Jin, Jiangen He
{"title":"Epidemiological characteristics and influencing factors of rehabilitation length of stay among hospitalized patients after knee arthroplasty in Beijing, China: a retrospective study.","authors":"Jun Liu, Yi Wang, Shasha Jin, Jiangen He","doi":"10.3389/fepid.2026.1919766","DOIUrl":"https://doi.org/10.3389/fepid.2026.1919766","url":null,"abstract":"<p><strong>Study design: </strong>Retrospective epidemiological study.</p><p><strong>Objectives: </strong>To analyze the epidemiological characteristics of patients receiving inpatient rehabilitation after knee arthroplasty, evaluate their rehabilitation LoS, and explore the factors influencing rehabilitation LoS.</p><p><strong>Methods: </strong>This retrospective study consecutively enrolled patients receiving inpatient rehabilitation after primary total or unicompartmental knee arthroplasty at a tertiary rehabilitation hospital in Beijing from 2023 to 2026. Data on demographics, insurance type, comorbidities, length of stay, Modified Barthel Index and hospitalization costs were collected. Statistical analyses included the Mann-Whitney U test, Spearman's rank correlation analysis, and a Gamma generalized linear model to explore predictors of rehabilitation length of stay.</p><p><strong>Results: </strong>Among all included admissions, there were 60 admissions (58.3%) covered by Beijing local medical insurance and 43 admissions (41.7%) with off-site medical insurance. The median length of rehabilitation stay was 25 days, and the median time to rehab admission from primary surgery to admission to the rehabilitation center was 5 days. The median total rehabilitation hospitalization cost was 28,337.1 Chinese Yuan (3,987.1 US dollars), among which rehabilitation training expenses accounted for 49.23%. After adjusting for confounding factors, only type of medical insurance was identified as an independent influencing factor of length of hospital stay (<i>P</i> < 0.05).</p><p><strong>Conclusions: </strong>This study implies that orthopedic hierarchical care and integrated rehabilitation models may help optimize rehabilitation length of stay and ease patients' economic burden. Further investigation of cross-institutional rapid referral pathways is needed.</p>","PeriodicalId":73083,"journal":{"name":"Frontiers in epidemiology","volume":"6 ","pages":"1919766"},"PeriodicalIF":2.9,"publicationDate":"2026-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13755175/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149413689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in epidemiologyPub Date : 2026-10-21eCollection Date: 2026-01-01DOI: 10.3389/fepid.2026.1933837
Hélio José Coelho-Júnior, Emanuele Marzetti
{"title":"Associations between Mediterranean lifestyle and its components with cardiovascular outcomes among community-dwelling older adults.","authors":"Hélio José Coelho-Júnior, Emanuele Marzetti","doi":"10.3389/fepid.2026.1933837","DOIUrl":"10.3389/fepid.2026.1933837","url":null,"abstract":"<p><strong>Aim: </strong>The present study examined the cross-sectional and longitudinal associations of adherence to the Mediterranean lifestyle (MEDLS) and its individual components with cardiovascular outcomes among older adults in England.</p><p><strong>Methods: </strong>Data from 565 adults aged ≥65 years participating in the English Longitudinal Study of Ageing were analyzed. MEDLS adherence (score range: 0-24) comprised six domains: Mediterranean diet adherence, physical activity, water intake, sleep, social isolation, and cooking activities. The outcomes of interest were hypertension, heart attack (myocardial infarction/coronary thrombosis), and stroke. Logistic regression models were used to examine cross-sectional and longitudinal associations, with analyses adjusted for age and sex.</p><p><strong>Results: </strong>Among 565 participants, 96 had hypertension, 14 had experienced a heart attack, and 10 had experienced a stroke at baseline; 42, 16, and 13 incident cases, respectively, were identified during follow-up. Higher MEDLS adherence was cross-sectionally associated with lower odds of hypertension (OR 0.849, 95% CI 0.722-0.999). No statistically significant longitudinal associations were observed between MEDLS and hypertension (OR 0.990, 95% CI 0.902-1.085), heart attack (OR 0.919, 95% CI 0.707-1.195), or stroke (OR 1.053, 95% CI 0.827-1.341), although the small number of events limited precision. At the component level, Mediterranean diet adherence was associated with lower odds of incident heart attack (OR 0.670, 95% CI 0.454-0.988); However, this finding was considered exploratory.</p><p><strong>Conclusion: </strong>Higher adherence to the MEDLS was associated with lower odds of prevalent hypertension but not with incident cardiovascular outcomes among communitydwelling older adults. At the component level, greater adherence to the Mediterranean diet was prospectively associated with lower odds of heart attack; however, given the absence of adjustment for multiple comparisons, this finding should be considered exploratory and requires confirmation in adequately powered studies.</p>","PeriodicalId":73083,"journal":{"name":"Frontiers in epidemiology","volume":"6 ","pages":"1933837"},"PeriodicalIF":2.9,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13731305/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149336271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in epidemiologyPub Date : 2026-10-19eCollection Date: 2026-01-01DOI: 10.3389/fepid.2026.1848489
Yuval Arbel, Israel Rachevski, Amichai Kerner, Miryam Kerner
{"title":"Socioeconomic gradients in diabetes prevalence across Israeli municipalities: the role of population density.","authors":"Yuval Arbel, Israel Rachevski, Amichai Kerner, Miryam Kerner","doi":"10.3389/fepid.2026.1848489","DOIUrl":"10.3389/fepid.2026.1848489","url":null,"abstract":"<p><strong>Background: </strong>Health policies often prioritize the most socioeconomically disadvantaged populations, implicitly assuming that health outcomes improve monotonically with socioeconomic status. However, this assumption may obscure important patterns in disease distribution and lead to suboptimal targeting of interventions.</p><p><strong>Methods: </strong>This study uses municipality-level data covering 127 Israeli municipalities to examine the relationship between municipal socioeconomic rank and diabetes prevalence and whether this relationship varies with population density. A quadratic specification interacted with population density is used to allow for non-linear gradients in health outcomes across different levels of density.</p><p><strong>Results: </strong>Diabetes prevalence is strongly negatively associated with socioeconomic rank at the municipal level, but the relationship between population density and diabetes prevalence varies across the socioeconomic distribution. Higher population density is associated with significantly lower diabetes prevalence among municipalities at SES ranks 1-3, whereas this association is not statistically significant at higher SES ranks. The quadratic SES component also becomes more negative as population density increases and is statistically significant at the 75th-percentile density, although this evidence of density-dependent curvature should be interpreted cautiously.</p><p><strong>Conclusions: </strong>These findings challenge the common assumption of a uniform socioeconomic gradient in health across different urban contexts. In the Israeli context, policies that focus primarily on socioeconomic status without considering population density may overlook important differences in disease burden. Incorporating interactions between socioeconomic gradients and population density, together with outcome-based indicators, may provide useful additional information for identifying heterogeneity in diabetes burden and informing the targeting of prevention strategies.</p>","PeriodicalId":73083,"journal":{"name":"Frontiers in epidemiology","volume":"6 ","pages":"1848489"},"PeriodicalIF":2.9,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13724543/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149328117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in epidemiologyPub Date : 2026-10-16eCollection Date: 2026-01-01DOI: 10.3389/fepid.2026.1931488
Marwah Farooqui, Monica Christmas, Gelila Goba, Lewis Hsu
{"title":"From menarche to menopause: a lifespan perspective on women's health in sickle cell disease.","authors":"Marwah Farooqui, Monica Christmas, Gelila Goba, Lewis Hsu","doi":"10.3389/fepid.2026.1931488","DOIUrl":"10.3389/fepid.2026.1931488","url":null,"abstract":"<p><p>Sickle cell disease (SCD) has long been associated with high childhood mortality and reduced life expectancy; however, advances in newborn screening, disease-modifying therapies, and comprehensive care have substantially improved survival. As increasing numbers of women with SCD reach midlife, new challenges are emerging that extend beyond the traditional focus on fertility and pregnancy. Despite growing recognition of reproductive health issues in SCD, menopause remains an underexplored and underrecognized phase of the disease trajectory. In this Perspective, we propose a lifespan framework for women's health in SCD that extends from menarche through menopause and healthy aging. We discuss how the underlying pathophysiology of SCD-including chronic hemolysis, inflammation, endothelial dysfunction, and progressive organ injury-intersects with reproductive transitions across the female life course. We highlight emerging evidence suggesting earlier menopause in women with SCD and examine the potential implications for pain burden, cognitive health, bone health, cardiovascular risk, iron overload, and quality of life. We further explore how symptom overlap between menopause and SCD may contribute to underdiagnosis and undertreatment during midlife. At the same time, we highlight the role of protective factors-including comprehensive multidisciplinary care, the development and evaluation of menopause-specific interventions through dedicated clinical trials in individuals with SCD, reproductive health services, and coordinated lifespan care models-in supporting healthy aging and improving long-term outcomes. Finally, we argue that menopause should be recognized as a critical component of comprehensive SCD care and research. Integrating reproductive aging into clinical practice, research agendas, and health policy represents an important opportunity to improve lifelong health outcomes, strengthen women-centered care, and advance health equity for women living with SCD worldwide.</p>","PeriodicalId":73083,"journal":{"name":"Frontiers in epidemiology","volume":"6 ","pages":"1931488"},"PeriodicalIF":2.9,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13719543/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149302556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Red blood cell distribution width and all-cause mortality in low-income populations: a NHANES-based cohort study.","authors":"Hui Ma, Yu-Han Li, Jin-Da Zhao, Yu-Wei Gu, Ren-Tao Zhu","doi":"10.3389/fepid.2026.1746886","DOIUrl":"https://doi.org/10.3389/fepid.2026.1746886","url":null,"abstract":"<p><strong>Background: </strong>Red blood cell distribution width (RDW) may be associated with all-cause mortality. This study aimed to evaluate the relationship between RDW and all-cause mortality in low-income populations. Low-income status was defined as a Family Income to Poverty Ratio (PIR) < 1, consistent with previous studies. All analyses were weighted to account for the complex sampling design.</p><p><strong>Methods: </strong>This study included 92,062 adults from the National Health and Nutrition Examination Survey (NHANES) 1999-2016 database, with survival follow-up through December 31, 2016. Analyses were restricted to the low-income subgroup and weighted according to the NHANES sampling design to ensure national representativeness. Linear and nonlinear multivariable Cox regression models were used to evaluate the association between RDW and all-cause mortality. Participants with missing data were excluded through complete-case analysis. Statistical analyses were performed using EmpowerStats and R software.</p><p><strong>Results: </strong>A total of 17,412 participants were included in the final analysis. In the low-income population, RDW showed a nonlinear association with all-cause mortality, characterized by a threshold at 15.9%. Below this threshold, each 1% increase in RDW was associated with a 29% higher risk of mortality (HR = 1.29, 95% CI: 1.20-1.38, <i>P</i> < 0.0001), while above 15.9%, the association was no longer statistically significant. Multivariable Cox regression analysis demonstrated that RDW remained significantly associated with mortality after adjustment for potential confounding factors (hazard ratio [HR] = 1.11, 95% confidence interval [CI]: 1.08-1.15, <i>P</i> < 0.0001). Specifically, each 1% increase in RDW was associated with an 11% increase in the risk of all-cause mortality.</p><p><strong>Conclusion: </strong>Elevated RDW was associated with increased all-cause mortality among low-income adults and may indicate a potential prognostic marker for mortality risk in this vulnerable population. However, further studies are needed to validate its clinical predictive utility.</p>","PeriodicalId":73083,"journal":{"name":"Frontiers in epidemiology","volume":"6 ","pages":"1746886"},"PeriodicalIF":2.9,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13710329/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149290346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in epidemiologyPub Date : 2026-10-12eCollection Date: 2026-01-01DOI: 10.3389/fepid.2026.1991472
Diego Ripamonti, Maria Santoro, Joseph Fokam, Francesca Ceccherini Silberstein, Josep M Llibre
{"title":"Editorial: Towards control of the HIV epidemic: trends in epidemiology and emerging drug resistance in the integrase inhibitor era.","authors":"Diego Ripamonti, Maria Santoro, Joseph Fokam, Francesca Ceccherini Silberstein, Josep M Llibre","doi":"10.3389/fepid.2026.1991472","DOIUrl":"10.3389/fepid.2026.1991472","url":null,"abstract":"","PeriodicalId":73083,"journal":{"name":"Frontiers in epidemiology","volume":"6 ","pages":"1991472"},"PeriodicalIF":2.9,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13696519/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149277946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in epidemiologyPub Date : 2026-10-08eCollection Date: 2026-01-01DOI: 10.3389/fepid.2026.1958489
Emily C Zabor, Nathan A Pennell, Sujata Patil
{"title":"Practical guidance for collecting reproducible time-to-event endpoints in retrospective observational oncology studies.","authors":"Emily C Zabor, Nathan A Pennell, Sujata Patil","doi":"10.3389/fepid.2026.1958489","DOIUrl":"https://doi.org/10.3389/fepid.2026.1958489","url":null,"abstract":"<p><p>Time-to-event endpoints such as progression-free survival, overall survival, and recurrence-free survival are among the most commonly reported outcomes in cancer research, yet the practical decisions required to collect and structure these data appropriately in retrospective observational studies remain poorly described in the literature. While substantial regulatory and methodological guidance exists for prospective clinical trials, investigators working with data collated retrospectively must navigate consequential decisions about index date selection, event definition, censoring, and follow-up time without equivalent support. Decisions at the data extraction stage can bias results and undermine reproducibility regardless of the rigor of the statistical analysis that follows. In this paper, we provide a practical, decision-focused guide to collating and updating time-to-event endpoints in retrospective oncology studies. Specific topics include how to define the index date, event date, and follow-up end date for different endpoints; what counts as an event and how competing events should be handled; how to manage missing and interval-censored data; how to update outcomes over time; and how to identify potential data quality issues through exploratory analysis and sensitivity testing. We illustrate key concepts using a publicly available lung cancer dataset and a worked example that follows endpoint creation from source records to analysis-ready variables, and we provide a practical checklist that researchers can apply directly to their own work. Our goal is to help epidemiologists, clinicians, and statisticians build time-to-event analyses on a foundation of rigorously collected data, resulting in more reliable and reproducible inference.</p>","PeriodicalId":73083,"journal":{"name":"Frontiers in epidemiology","volume":"6 ","pages":"1958489"},"PeriodicalIF":2.9,"publicationDate":"2026-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13687036/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149277997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in epidemiologyPub Date : 2026-09-28eCollection Date: 2026-01-01DOI: 10.3389/fepid.2026.1943268
Martha Fors, Paloma González, Ariel Torres, Lizbeth Silva-Guayasamín, Christian Silva-Sarabia
{"title":"Cancer prevention and interception studies registered in ClinicalTrials.gov: a landscape analysis of trial characteristics and reporting gaps.","authors":"Martha Fors, Paloma González, Ariel Torres, Lizbeth Silva-Guayasamín, Christian Silva-Sarabia","doi":"10.3389/fepid.2026.1943268","DOIUrl":"https://doi.org/10.3389/fepid.2026.1943268","url":null,"abstract":"<p><strong>Background: </strong>Cancer interception has emerged as a prevention-oriented approach that seeks to intervene during early stages of carcinogenesis, before the development of clinically manifest invasive disease. However, the extent to which prevention and interception research is represented and classified in clinical trial registries remains unclear.</p><p><strong>Methods: </strong>We conducted a cross-sectional, registry-based analysis of cancer prevention and interception-related studies registered in ClinicalTrials.gov through September 2025. Records identified using terms related to cancer prevention, interception, chemoprevention, risk reduction, premalignant lesions, precursor lesions, and minimal residual disease were screened for eligibility. Study characteristics, including study type, recruitment status, participant eligibility, enrollment, intervention model, allocation, masking, cancer localization, study phase, and funding category, were summarized descriptively. Associations between categorical variables were assessed using exact tests when appropriate.</p><p><strong>Results: </strong>Among 209 eligible studies, 157 (75.1%) were interventional and 52 (24.9%) were observational. Most studies included adults and older adults, and 52.6% were classified as completed. Among interventional studies, randomized allocation and parallel-group designs predominated, while most studies were unmasked. Gynecological and gastrointestinal malignancies were the most frequently represented cancer localizations. Funding was classified as 'Other' in most records, reflecting a heterogeneous registry category that could not be further disaggregated. Study type was associated with funding category (<i>p</i> = 0.028), whereas the association between study type and cancer localization was not statistically significant (<i>p</i> = 0.09, with a Cramér's V of 0.32). Among interventional studies, 54 (34.4%) focused on early detection and diagnosis, aligning with the registry's 'Screening' and 'Diagnostic' fields. Cancer interception and post-treatment disease control accounted for 52 studies (33.1%) but lacked distinct registry designations, while 51 (32.5%) addressed primary prevention and chemoprevention, corresponding to the 'Prevention' category.</p><p><strong>Conclusions: </strong>Cancer prevention and interception research registered in ClinicalTrials.gov is heterogeneous and encompasses distinct clinical objectives. Our findings highlight the need for explicit operational definitions and more granular, standardized reporting fields to improve the visibility, interpretability, and comparability of preventive oncology.</p>","PeriodicalId":73083,"journal":{"name":"Frontiers in epidemiology","volume":"6 ","pages":"1943268"},"PeriodicalIF":2.9,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13685697/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149247767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Frontiers in epidemiologyPub Date : 2026-09-18eCollection Date: 2026-01-01DOI: 10.3389/fepid.2026.1817539
Martha N Kivecu, Victor Mobegi, Cavin Mgawe, Brenda M Kania, Gladys C Chemwor, Raphael O Okoth, Edwin W Mwakio, George Obiero, Jennifer M Mutisya, Jackline A Juma, Agnes C Cheruiyot, Benjamin H Opot, Amanda L Roth, Bernhards R Ogutu, Dennis W Juma, Lynette Isabella Ochola-Oyier, Ben Andagalu, Hoseah M Akala
{"title":"Low prevalence of <i>Plasmodium falciparum pfhrp</i>2 and <i>pfhrp</i>3 gene deletions in archived samples collected before and after nationwide malaria-RDT rollout in Kenya.","authors":"Martha N Kivecu, Victor Mobegi, Cavin Mgawe, Brenda M Kania, Gladys C Chemwor, Raphael O Okoth, Edwin W Mwakio, George Obiero, Jennifer M Mutisya, Jackline A Juma, Agnes C Cheruiyot, Benjamin H Opot, Amanda L Roth, Bernhards R Ogutu, Dennis W Juma, Lynette Isabella Ochola-Oyier, Ben Andagalu, Hoseah M Akala","doi":"10.3389/fepid.2026.1817539","DOIUrl":"https://doi.org/10.3389/fepid.2026.1817539","url":null,"abstract":"<p><p>Rapid and accurate malaria diagnosis is essential for effective treatment and malaria control. In Kenya, most malaria testing relies on <i>P. falciparum</i> histidine-rich protein 2 (PfHRP2)-based rapid diagnostic tests (RDTs). However, deletions in the <i>pfhrp</i>2/<i>pfhrp</i>3 genes can lead to false-negative RDT results, which can sustain transmission and worsen clinical outcomes. This study assessed the prevalence and pattern of <i>pfhrp</i>2, <i>pfhrp</i>3 and their respective flanking genes in archived samples collected before and after the nationwide rollout of PfHRP2-based RDTs in Kenya in 2012. A total of 350 archived whole-blood samples were analysed, comprising 95 pre-RDT samples (collected before the nationwide rollout of RDTs in Kenya) from 2003 to 2005 and 255 post-RDT samples (collected after the nationwide rollout of RDTs in Kenya) from 2013 to 2017 from multiple malaria-endemic regions of Kenya. Samples were first screened by quantitative Real-Time PCR to identify those with adequate parasite density for genotyping. Nested PCR assays were then used to genotype <i>pfhrp</i>2, <i>pfhrp</i>3 and their flanking genes. Where available, PfHRP2-based RDT results were compared with molecular genotyping outcomes to investigate potential causes of false-negative RDT results. The overall prevalence of single <i>pfhrp</i>2 or <i>pfhrp</i>3 deletions was low, at 0.3% (1/317) and 1.3% (4/317), respectively. All pre-RDT samples carried intact <i>pfhrp</i>2 and <i>pfhrp</i>3 genes. Among post-RDT samples, deletions were rare 0.4% (1/224) for <i>pfhrp</i>2 gene only and 1.8% (4/224) for <i>pfhrp</i>3 gene only<i>.</i> No sample exhibited a triple deletion of <i>pfhrp</i>2 and both of its flanking genes or triple deletion of <i>pfhrp</i>3 and both of its flanking genes. The sensitivity of the PfHRP2-based RDT was 89.2% (174/195). Notably, 95.2% of false-negative RDT results occurred in samples with intact <i>pfhrp</i>2 and <i>pfhrp</i>3, suggesting that low parasitemia or other factors, rather than gene deletions, were the primary cause of diagnostic failure. Overall, <i>pfhrp</i>2 and <i>pfhrp</i>3 deletions remained rare in the samples collected up to five years after the nationwide rollout of PfHRP2-RDTs in Kenya. However, continuous molecular surveillance is essential to identify emerging deletion hotspots and to ensure the sustained reliability of PfHRP2-based diagnostics as testing practices and parasites continue to evolve.</p>","PeriodicalId":73083,"journal":{"name":"Frontiers in epidemiology","volume":"6 ","pages":"1817539"},"PeriodicalIF":2.9,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13630768/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149119186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}